Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. - Wikidata - wikimedia - TriplyDB

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

http://www.wikidata.org/entity/Q34266403

about

Long term hormone therapy for perimenopausal and postmenopausal women Hormone replacement therapy for women previously treated for endometrial cancer Summary of the American College for Advancement in Medicine May 2005 Conference European guidance for the diagnosis and management of osteoporosis in postmenopausal women Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]Influences of obese (ob/ob) and diabetes (db/db) genotype mutations on lumber vertebral radiological and morphometric indices: skeletal deformation associated with dysregulated systemic glucometabolism.Hormone replacement therapy for women previously treated for endometrial cancer Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives Prescribing menopausal hormone therapy: an evidence-based approach Bioidentical hormone therapy Pharmacology of estrogens and progestogens: influence of different routes of administration Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement Long-term hormone therapy for perimenopausal and postmenopausal women.Description of an Audio-Based Paced Respiration Intervention for Vasomotor Symptoms.Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.Advances in hormone replacement therapy: making the menopause manageable Postmenopausal estrogen and progestin effects on the serum proteome.TGFβ inducible early gene-1 plays an important role in mediating estrogen signaling in the skeleton Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.Long-term supplementation with young coconut juice does not prevent bone loss but rather alleviates body weight gain in ovariectomized rats Osteoporosis: "A risk factor for periodontitis"An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.Methanol Extract of Euchelus asper Prevents Bone Resorption in Ovariectomised Mice Model.Pre-screening young postmenopausal women for BMD testing.Estrogen therapy and bone mineral density in African-American and Caucasian women Racial/ethnic differences in bone mineral density among older women.Safety of drugs used in the treatment of osteoporosis.Off-label use of hormones as an antiaging strategy: a review American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis The 2012 hormone therapy position statement of: The North American Menopause Society.Emerging therapeutic opportunities for skeletal restoration.Use of oral bisphosphonates by older adults with fractures and impaired renal function A second chance for hormone replacement therapy?Progesterone and bone: actions promoting bone health in women.

P2860

Q24201974-02DFD812-2DF4-4DA8-959E-B5D8796DA490 Q24234201-54A2AD86-1115-4CA3-A47F-349D77E6D1F1 Q24530126-885A8BB6-0B0D-4401-8EDE-D01AD3C7DB20 Q24612411-D3122144-F146-4327-B8E3-9B1F2C0DC304 Q24626206-1885CF62-34A0-4FF0-BF76-BA3EA5350E62 Q24658109-0CF4785B-6412-459B-A343-D04270C3410B Q24796830-E800022D-ECCD-4C26-9967-8AC00D2A6A87 Q25257772-698FCBE7-DF06-4405-987B-8D1B18F7F138 Q26471218-4B4833B9-1ABB-4FC5-91C1-16B6AF98A8B0 Q26744057-D49D38F7-7BF7-4A23-A17A-4C809A595B2A Q26864207-8FDDD11D-0C0A-44C8-A0BB-5A2EC814C6AA Q27005978-170E36DC-4428-437E-98B4-A312485F322F Q27022920-F4B88576-4F3F-475B-BD56-394478ADC536 Q27691410-4BD1713A-1D2C-4BC4-BF5A-0DAB79419116 Q28268346-DDB443A5-72B8-4705-8F5F-14D30F608DB4 Q28388174-2F8827CC-59E9-4D65-80DE-316E0679202E Q30238978-2D8691B2-1411-456B-BFFE-D9137D0FF946 Q30352600-E103FF93-B402-4591-BE35-09733D6306DB Q30879035-359FCCD9-9B81-43B8-87E0-A76B0EA71F5C Q30940476-5EC2BF72-331C-417D-8C24-F57362F1D115 Q33387664-4ADFB1C0-20BA-4DB5-BE05-F97B95180A9A Q33600109-6634AC9B-788F-431A-BFFD-C368D72B519D Q33640377-C50B1B38-D99C-49C7-9146-D56FBD5086EA Q33642558-0780ABE3-AD56-4366-919B-ABA53E67E415 Q33661422-BB0F2E29-B8CE-4DAC-9DE2-516C0FEDC497 Q33685435-53C95AA6-0CA8-4A52-BAD9-1168258E8010 Q33759893-78FE3438-9E53-46B6-9F93-4E1900C98EB4 Q33780223-39AB3BD5-ECBF-46AC-B43D-93FF2F2E2877 Q33796822-730A1094-F6EF-4E4D-8398-82654B86808F Q33833419-031415E0-AEFD-4C8D-B204-8BF272D9A534 Q33880902-2F421666-A293-4B55-AAF1-FD24B1942205 Q33944962-D72ADF94-2C5F-4609-A8EF-B7E5EC4A8C08 Q33949479-EB70092E-FCE3-451E-8F5B-3C25C8CF3D15 Q33976165-C8D89A15-0556-4B32-BC1E-42668B9CAB74 Q34158441-05E0DA16-BC76-45A2-B26B-B8EF9440FF00 Q34161400-36720787-934A-46D0-BFA8-884915F59C9F Q34161867-BAE7E7BC-6D6C-4523-9AC1-4E237FE4B747 Q34220843-21366BB9-CE22-4861-A38C-4051DA4288DC Q34250612-2EC82DB5-795F-46B3-B5CE-53FCD3C7C5AE Q34261512-8D377AB6-2B5D-48B1-8398-CF575C3BFE7C

P2860

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

http://www.wikidata.org/entity/Q34266403

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Effects of estrogen plus proge ...... h Initiative randomized trial.

@ast

Effects of estrogen plus proge ...... h Initiative randomized trial.

@en

Effects of estrogen plus proge ...... h Initiative randomized trial.

@nl

type

label

Effects of estrogen plus proge ...... h Initiative randomized trial.

@ast

Effects of estrogen plus proge ...... h Initiative randomized trial.

@en

Effects of estrogen plus proge ...... h Initiative randomized trial.

@nl

prefLabel

Effects of estrogen plus proge ...... h Initiative randomized trial.

@ast

Effects of estrogen plus proge ...... h Initiative randomized trial.

@en

Effects of estrogen plus proge ...... h Initiative randomized trial.

@nl

P1433

Q34266403-23405061-BE63-41C5-A6AD-4A97C96D8AEA

P1476

Q34266403-530CD8F2-A723-457B-985E-E3DB5153D85A

P2093

Q34266403-12C49F88-AF16-4AD6-A3FD-D28E59498DB9

Q34266403-2EDA21E7-1C6C-4D30-9389-006554E15C13

Q34266403-6081A996-56E4-416E-87AC-F17AAD55E28A

Q34266403-8E49744F-2ABA-4AAC-B475-071B5F53F7F9

Q34266403-902B6C63-D774-469C-A568-FF94BAA80DC7

Q34266403-A0AE09E2-9157-424D-80C8-A67D42B0BE0A

Q34266403-AA79E950-99BD-442B-B85D-E7DC8820AF3F

Q34266403-CFADBB52-F2C7-4CE3-8B3B-08B1C559894A

Q34266403-E4DE9FAE-F3CE-4B3F-B8A9-A15480A5D042

Q34266403-EF1A7F62-EDCA-44C4-9648-F25E88EECFF1

P304

Q34266403-08DBA92C-8117-4D82-AA19-1940FB9C560D

P31

Q34266403-DB09CD81-9D95-4179-AF9C-E30C30F57DA0

P356

Q34266403-1D3C8F3E-18E8-4C3D-A968-3054F983224F

P407

Q34266403-9392BBCA-FD34-442C-9D4A-DE30DD6678B1

P433

Q34266403-3EC80FE1-92AB-48CA-AF52-D36679B692F2

P478

Q34266403-0194E6E7-A0D2-448E-9A16-B20C7386BC10

P50

Q34266403-4587EB82-7A92-4B9F-849A-535DD0BE864C

Q34266403-95d5512b-4b36-65cf-2c87-d7556a4ad71d

Q34266403-A190A296-17D6-44F6-8EFF-012DFFA2B988

Q34266403-C1893D2C-DEC4-4B20-86A3-7BF3814AD56B

Q34266403-C3460B74-4260-46CC-84C7-F70581A41502

P577

Q34266403-A4983AC8-311B-4B85-8509-B9D719363D31

P5875

Q34266403-28082A9A-86E8-4D76-A829-A8D4F470CC8B

P698

Q34266403-AA39ABFF-B8C6-4574-A26A-D9742735CC3F

P356

JAMA.290.13.1729

P1433

Journal of the American Medical Association

P1476

Effects of estrogen plus proge ...... h Initiative randomized trial.

@en

P2093

Andrea Z LaCroix

http://www.w3.org/2001/XMLSchema#string

Joan McGowan

http://www.w3.org/2001/XMLSchema#string

Joan Neuner

http://www.w3.org/2001/XMLSchema#string

John Robbins

http://www.w3.org/2001/XMLSchema#string

Marcia L Stefanick

http://www.w3.org/2001/XMLSchema#string

Mary Pettinger

http://www.w3.org/2001/XMLSchema#string

Meryl LeBoff

http://www.w3.org/2001/XMLSchema#string

Nelson B Watts

http://www.w3.org/2001/XMLSchema#string

Steven R Cummings

http://www.w3.org/2001/XMLSchema#string

Women's Health Initiative Investigators

http://www.w3.org/2001/XMLSchema#string

P304

1729-1738

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.290.13.1729

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

290

http://www.w3.org/2001/XMLSchema#string

P50

Jean Wactawski-Wende

Women's Health Initiative Investigators

Rebecca D. Jackson

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9071218

http://www.w3.org/2001/XMLSchema#string

P698

14519707

http://www.w3.org/2001/XMLSchema#string